Skip to main content
SpringerLink
Log in

Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data sets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

References

  1. Dumitrescu L, Papathanasiou A, Coclitu C et al (2023) An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother 24:495–509

    Article  PubMed  PubMed Central  Google Scholar 

  2. Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K (2016) Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm 2016:8606878

    PubMed  PubMed Central  Google Scholar 

  3. Jana A, Pahan K (2010) Sphingolipids in multiple sclerosis. NeuroMol Med 12:351–361

    Article  CAS  Google Scholar 

  4. Chun J, Giovannoni G, Hunter SF (2021) Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs 81:207–231

    Article  CAS  PubMed  Google Scholar 

  5. Fischer S, Proschmann U, Akgün K, Ziemssen T (2021) Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells 10:3177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Swallow E, Patterson-Lomba O, Yin L et al (2020) Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res 9:275–285

    Article  PubMed  Google Scholar 

  7. Swallow E, Pham T, Patterson-Lomba O et al (2023) Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: a matching-adjusted indirect comparison. Mult Scler Relat Disord 71:104551

    Article  CAS  PubMed  Google Scholar 

  8. Caliendo D, Grassia MC, Carotenuto A et al (2024) Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia. Mult Scler Relat Disord 81:105135

    Article  CAS  PubMed  Google Scholar 

  9. Zecca C, Merlini A, Disanto G et al (2018) Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: observational study. Mult Scler 24:167–174

    Article  CAS  PubMed  Google Scholar 

  10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (2012) National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547852/. Accessed 14 Feb 2024

Download references

Funding

This article was written in the absence of any intellectual, commercial or financial relationships that could represent a potential conflict of interest.

Author information

Authors and Affiliations

  1. Multiple Sclerosis Center, Neurology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy

    Simone Guerrieri, Martina Rubin, Irene Gattuso, Chiara Zanetta, Angela Genchi, Paolo Preziosa, Maria Assunta Rocca, Massimo Filippi & Lucia Moiola

  2. Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Martina Rubin, Paolo Preziosa, Maria Assunta Rocca & Massimo Filippi

  3. Vita-Salute San Raffaele University, Milan, Italy

    Martina Rubin, Irene Gattuso, Angela Genchi, Paolo Preziosa, Maria Assunta Rocca & Massimo Filippi

  4. Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Massimo Filippi

  5. Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Massimo Filippi

Authors
  1. Simone Guerrieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene Gattuso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Zanetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Angela Genchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paolo Preziosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Assunta Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Massimo Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lucia Moiola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Filippi.

Ethics declarations

Conflicts of interest

SG received compensation for speaking activities from Bristol Squibb Meyer, Novartis, Merck. MR and IG have nothing to disclose. CZ received compensation for speaking activities and/or consulting activities from Biogen, Bristol Myers Squibb, Janssen, Roche, Astrazeneca, Sanofi, Merck, Alexion, Novartis. AG received compensation for speaking activities from Novartis. PP received speaker honoraria from Roche, Biogen, Novartis, Merck Serono, Bristol Myers Squibb and Genzyme; he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. MAR received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders. MF is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. LM received compensations for speaking activities and/or for participating to advisory board from Merck, Celgene, Biogen, Sanofi, Novartis, Roche, Alexion.

Ethical approval and informed consent

The present study was conducted in accordance to the Helsinki Declaration (Fortaleza revision, 2013) and with European and Italian regulations about privacy. Informed consent was obtained from patients.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guerrieri, S., Rubin, M., Gattuso, I. et al. Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series. J Neurol (2024). https://doi.org/10.1007/s00415-024-12342-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00415-024-12342-z

Search

Navigation